Grace Therapeutics FY27 Q1 net loss widens to $15.79 million; operating loss widens to $15.92 million

Reuters2026/08/13 11:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Grace Therapeutics posted a net loss of USD 15.79 million, widening from USD 3.36 million in the year-ago quarter.
Loss per share widened to USD 0.91 from USD 0.21, reflecting a USD 13.53 million impairment of intangible assets.
Research and development expense fell 27.02% to USD 697,000, while general and administrative costs declined 20.98% to USD 1.69 million.
Cash and cash equivalents ended the quarter at USD 13.76 million, down from USD 16.98 million at March 31, 2026.
FDA issued a Complete Response Letter for GTx-104; a dual-source manufacturing strategy is underway ahead of an NDA resubmission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032632), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Grace Therapeutics FY27 Q1 net loss widens to $15.79 million; operating loss widens to $15.92 million

You may also like

Crypto prices